With the increasing use of neoadjuvant targeted therapy for HER2-positive tumor, the prognostic value of CPS + EG staging system [22] was partly compromised due to favorable response of HER2-positive tumor to trastuzumab combined with chemotherapy, leading to the birth of the Neo-Bioscore that significantly improved the predictive performance of 5-year disease-specific survival (DSS) compared to the CPS + EG staging system [23]. Here, ERBB2 is linked to neoplasm.